Braze Inc vs Medpace Holdings Inc — how do they compare? Braze Inc trades at $28.27 (market cap $3.18B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 5.3× Braze Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| BRZE | MEDP | |
|---|---|---|
Market Cap | $3.18B | $16.90B |
Sector | Technology | Technology |
52-Week High | $36.19 | $620.59 |
52-Week Low | $15.79 | $393.42 |
Enterprise Value | $2.87B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
Braze (BRZE) trades at $27.50, down 4.35% today but showing strong technical momentum with bullish moving averages. The company demonstrates impressive revenue growth, reaching $593.41 million in 2025 with 30% year-over-year expansion, though profitability remains elusive with a -15.51% net margin. Recent news highlights insider selling but also strong AI-driven customer engagement demand and four consecutive quarters of organic revenue acceleration.
The outlook remains positive with 96% analyst buy ratings and a $34.78 consensus target suggesting 26% upside. Key risks include persistent unprofitability despite growth and competitive pressures in the customer engagement software space. The stock's trajectory depends on continued revenue acceleration and eventual path to profitability.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →